Author: admin

DelveInsight’s “Asthma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Asthma, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Asthma Market Forecast

Some of the key facts of the Asthma Market Report:

• The asthma market size in the 7MM was around ~USD 19,000 million in 2023, with expectations of growth throughout the forecast period from 2024 to 2034.

• In February 2025, Enveda, a biotechnology company leveraging AI to transform natural compounds into innovative medicines, is excited to announce the expansion of its lead asset, ENV-294, into a second indication: asthma. Originally developed for atopic dermatitis, this novel therapy offers a groundbreaking approach to treating respiratory inflammatory conditions. To support this progress, Enveda has established an advisory board featuring top experts in asthma research and treatment.

• In September 2024, Kinaset Therapeutics revealed plans for two oral presentations and a late-breaking poster presentation at the 2024 European Respiratory Society (ERS) Congress. These presentations highlight the potential of Kinaset’s lead clinical candidate, frevecitinib (KN-002), as a treatment for patients with moderate to severe asthma and those with COPD

• The market size in the 7MM is expected to grow at a compound annual growth rate (CAGR) of approximately 3.9%, driven by rising disease awareness and the introduction of new drugs.

• In 2023, the UK had the largest market size among EU countries, totaling USD 1.3 million, whereas Spain had the smallest market size at USD 0.4 million.

• The recent 2024 American Thoracic Society (ATS) conference addressed a wide range of asthma-related topics, from real-world experiences and biomarkers to pediatric asthma and innovative treatments. The conference highlighted significant advancements in asthma research and treatment, including clinical remission indicators and new therapies like inhaled JAK inhibitors and oral STAT6 degraders.

• The patent protection for the syringe formulation of XOLAIR in the United States and Europe is anticipated to conclude between 2024 and 2025. Currently, there is no presence of generic competition in either the United States or the European Union.

• CINQAIR possesses biological exclusivity in the United States until 2028 and is granted regulatory exclusivity in Europe until 2026.

• The collective number of diagnosed prevalent cases of asthma in the 7MM was approximated to be 55 million cases in 2022. Among these cases, the adult population had the highest diagnosed prevalent cases, and this number is anticipated to rise by 2032.

• As per the World Health Organization (WHO) in 2022, asthma represents a significant non-communicable disease impacting individuals across various age groups, with children being particularly susceptible. It stands as the most prevalent chronic ailment among children. In 2019, approximately 262 million individuals were affected by asthma, resulting in 455,000 deaths.

• Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others

• Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others

• The Asthma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Asthma pipeline products will significantly revolutionize the Asthma market dynamics.

Asthma Overview

Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. These symptoms often occur in response to triggers such as allergens, irritants, exercise, or respiratory infections.

Get a Free sample for the Asthma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/asthma-market

Asthma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Asthma Epidemiology Segmentation:

The Asthma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Asthma

• Prevalent Cases of Asthma by severity

• Gender-specific Prevalence of Asthma

• Diagnosed Cases of Episodic and Chronic Asthma

Download the report to understand which factors are driving Asthma epidemiology trends @ Asthma Epidemiology Forecast

Asthma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Asthma market or expected to get launched during the study period. The analysis covers Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Asthma Therapies and Key Companies

• GSK3511294 (Depemokimab): GlaxoSmithKline

• Masitinib (AB07105): AB Science

• PT010: AstraZeneca

• Dexpramipexole Dihydrochloride: Areteia Therapeutics

• ARS 1: ARS Pharmaceuticals, Inc.

• MEDI3506 (tozorakimab): AstraZeneca

• AZD1402 (PRS-060): Pieris Pharma/AstraZeneca

• Atuliflapon (AZD5718): AstraZeneca

• Amlitelimab: Sanofi

• Rilzabrutinib: Sanofi

• BOXABAN (Ifetroban): Cumberland Pharmaceuticals

• RG6341 (GDC-6599): Genentech Research/Roche

• CBP-201: Suzhou Connect Biopharmaceuticals

• AVTX-002 (Quisovalimab): Avalo Therapeutics

• MRx-4DP0004: 4D Pharma plc

• SB010: Sterna Biologicals

Discover more about therapies set to grab major Asthma market share @ Asthma Treatment Landscape

Asthma Market Strengths

• Robust pipeline of drugs targeting a variety of different and more effective pathogenic mechanisms in asthma.

Asthma Market Opportunities

• Availability of varied formulation types and convenient dosing schedules for more effective treatment.

Scope of the Asthma Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others

• Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others

• Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies

• Asthma Market Dynamics: Asthma market drivers and Asthma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Asthma Unmet Needs, KOL’s views, Analyst’s views, Asthma Market Access and Reimbursement

To know more about Asthma companies working in the treatment market, visit @ Asthma Clinical Trials and Therapeutic Assessment

Table of Contents

1. Asthma Market Report Introduction

2. Executive Summary for Asthma

3. SWOT analysis of Asthma

4. Asthma Patient Share (%) Overview at a Glance

5. Asthma Market Overview at a Glance

6. Asthma Disease Background and Overview

7. Asthma Epidemiology and Patient Population

8. Country-Specific Patient Population of Asthma

9. Asthma Current Treatment and Medical Practices

10. Asthma Unmet Needs

11. Asthma Emerging Therapies

12. Asthma Market Outlook

13. Country-Wise Asthma Market Analysis (2020–2034)

14. Asthma Market Access and Reimbursement of Therapies

15. Asthma Market Drivers

16. Asthma Market Barriers

17. Asthma Appendix

18. Asthma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asthma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmac, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma

DelveInsight’s “Pediatric Obesity Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Pediatric Obesity, historical and forecasted epidemiology as well as the Pediatric Obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Pediatric Obesity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pediatric Obesity Market Forecast

Some of the key facts of the Pediatric Obesity Market Report:

• The Pediatric Obesity market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In September 2024, Novo Nordisk highlighted the effectiveness of its obesity treatment, Saxenda (liraglutide), in children under 12 through positive Phase III trial results. Participants receiving Saxenda experienced an average reduction of 5.8% in body mass index (BMI), whereas the placebo group saw a decrease of only 1.6%. The Phase III trial findings were presented at the European Association for the Study of Diabetes (EASD) conference in Spain.

• In 2023, around 8 million children aged 5 to 19 were affected by obesity across the 7MM. With ongoing lifestyle trends, this figure is anticipated to rise substantially in the coming years.

• Research indicates that the prevalence of overweight, including obesity, among children and adolescents aged 5–19 has surged from 8% in 1990 to 20% in 2022. This increase has been observed in both genders, with 19% of girls and 21% of boys classified as overweight in 2022.

• Among the EU4 and the UK, Germany recorded the highest prevalence of childhood obesity cases, while Spain had the lowest.

• Rhythm Pharmaceuticals intends to file a supplemental New Drug Application (sNDA) with the US FDA in Q2 2024 to extend IMCIVREE’s label to include children aged 2 to 6 years

• Key Pediatric Obesity Companies: Novo Nordisk, Eli Lilly and Company, VIVUS LLC, Novartis, Rhythm Pharma, Jack Yanovski, and others

• Key Pediatric Obesity Therapies: WEGOVY (semaglutide), SAXENDA (liraglutide), Tirzepatide, VI-0521, Sandostatin LAR, Setmelanotide, Orlistat, and others

• The Pediatric Obesity market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pediatric Obesity pipeline products will significantly revolutionize the Pediatric Obesity market dynamics.

Pediatric Obesity Overview

Pediatric obesity refers to the condition of having excess body fat in children and adolescents. It is a complex medical condition characterized by an abnormal or excessive accumulation of fat that may negatively affect a child’s health and well-being.

Get a Free sample for the Pediatric Obesity Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/pediatric-obesity-market

Pediatric Obesity Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pediatric Obesity Epidemiology Segmentation:

The Pediatric Obesity market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Pediatric Obesity

• Prevalent Cases of Pediatric Obesity by severity

• Gender-specific Prevalence of Pediatric Obesity

• Diagnosed Cases of Episodic and Chronic Pediatric Obesity

Download the report to understand which factors are driving Pediatric Obesity epidemiology trends @ Pediatric Obesity Epidemiology Forecast

Pediatric Obesity Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pediatric Obesity market or expected to get launched during the study period. The analysis covers Pediatric Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pediatric Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pediatric Obesity Therapies and Key Companies

• WEGOVY (semaglutide): Novo Nordisk

• SAXENDA (liraglutide): Novo Nordisk

• Tirzepatide: Eli Lilly and Company

• VI-0521: VIVUS LLC

• Sandostatin LAR: Novartis

• Setmelanotide: Rhythm Pharmaceuticals

• Orlistat: Jack Yanovski

Discover more about therapies set to grab major Pediatric Obesity market share @ Pediatric Obesity Treatment Landscape

Scope of the Pediatric Obesity Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Pediatric Obesity Companies: Novo Nordisk, Eli Lilly and Company, VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski, and others

• Key Pediatric Obesity Therapies: WEGOVY (semaglutide), SAXENDA (liraglutide), Tirzepatide, VI-0521, Sandostatin LAR, Setmelanotide, Orlistat, and others

• Pediatric Obesity Therapeutic Assessment: Pediatric Obesity current marketed and Pediatric Obesity emerging therapies

• Pediatric Obesity Market Dynamics: Pediatric Obesity market drivers and Pediatric Obesity market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Pediatric Obesity Unmet Needs, KOL’s views, Analyst’s views, Pediatric Obesity Market Access and Reimbursement

To know more about Pediatric Obesity companies working in the treatment market, visit @ Pediatric Obesity Clinical Trials and Therapeutic Assessment

Table of Contents

1. Pediatric Obesity Market Report Introduction

2. Executive Summary for Pediatric Obesity

3. SWOT analysis of Pediatric Obesity

4. Pediatric Obesity Patient Share (%) Overview at a Glance

5. Pediatric Obesity Market Overview at a Glance

6. Pediatric Obesity Disease Background and Overview

7. Pediatric Obesity Epidemiology and Patient Population

8. Country-Specific Patient Population of Pediatric Obesity

9. Pediatric Obesity Current Treatment and Medical Practices

10. Pediatric Obesity Unmet Needs

11. Pediatric Obesity Emerging Therapies

12. Pediatric Obesity Market Outlook

13. Country-Wise Pediatric Obesity Market Analysis (2020–2034)

14. Pediatric Obesity Market Access and Reimbursement of Therapies

15. Pediatric Obesity Market Drivers

16. Pediatric Obesity Market Barriers

17. Pediatric Obesity Appendix

18. Pediatric Obesity Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pediatric Obesity Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski

The multiple myeloma treatment paradigm is undergoing a dynamic evolution, marked by increasing therapeutic interventions by companies such as Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie/Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., and others.

DelveInsight’s comprehensive report titled “Multiple Myeloma Market Insight, Epidemiology And Market Forecast – 2034“ offers an in-depth market analysis from 2020 to 2034. The analysis encompasses historical data, future projections of market size, detailed epidemiological trends, an assessment of the competitive landscape, and an evaluation of current and emerging therapeutic approaches.

According to DelveInsight’s findings, the total Multiple Myeloma market size across the 7MM was USD 21.5 Billion in 2023. This market is anticipated to experience continued positive growth through 2034. The United States held the largest share of the 7MM market, accounting for USD 14.5 Billion in 2023. This highlights the significant market opportunity within the United States.

Download the Multiple Myeloma market report to understand which factors are driving the Multiple Myeloma therapeutic market @ Multiple Myeloma Market Trends

The epidemiological landscape of Multiple Myeloma in the 7MM reveals that the total incidence of the disease was approximately 76K cases in 2024. This number is projected to rise over the coming years. Notably, the highest incidence of Multiple Myeloma is observed in individuals aged 65 years and above. Furthermore, the disease is more prevalent in men than in women, with over 50% of males in the United States diagnosed with multiple myeloma.

The DelveInsight report provides a comprehensive breakdown of this epidemiological data, including total incident cases of multiple myeloma, total symptomatic cases of multiple myeloma, gender-specific cases of multiple myeloma, age-specific cases of multiple myeloma, transplant-eligible cases of multiple myeloma, and treated patient pool across all lines of therapies.

Currently, the treatment landscape for Multiple Myeloma involves a variety of approaches, including chemotherapy, immunotherapy, targeted therapy, corticosteroids, and stem cell transplantation. Significant progress has been made with the development and approval of novel therapies such as immunomodulatory drugs (IMiDs), proteasome inhibitors, and monoclonal antibodies, which have improved patient outcomes. The treatment paradigm continues to evolve with the emergence of innovative strategies like CAR-T cell therapies and bispecific antibodies, offering new hope, particularly for patients with relapsed or refractory disease.

Discover evolving trends in the Multiple Myeloma treatment landscape @ Multiple Myeloma Therapeutics Market

Despite these significant advancements, challenges persist in the management of Multiple Myeloma, most notably the issue of disease relapse and the development of resistance to multiple drugs. The future treatment strategies are therefore focused on overcoming this resistance and achieving more durable responses. The developmental pipeline remains robust, with key pharmaceutical companies such as Regeneron (Linvoseltamab), Bristol Myers Squibb (Mezigdomide and Alnuctamab), AbbVie and Roche (VENCLEXTA), and Opna Bio (OPN-6602), among others, actively involved in bringing novel therapies to market.

Recent developments highlight ongoing innovation in multiple myeloma treatment. In February 2025, Opna Bio’s OPN-6602 received FDA Orphan Drug designation for multiple myeloma, while in April 2024, the FDA approved Bristol-Myers Squibb and Bluebird Bio’s ABECMA for the treatment of adult patients with relapsed or refractory multiple myeloma. These milestones, along with a robust pipeline of emerging therapies, continue to reshape the multiple myeloma treatment landscape, offering new hope for patients.

Unlock which Multiple Myeloma drug is expected to capture the largest market share in 7MM by 2032. Visit the Multiple Myeloma Market Insights

In conclusion, the Multiple Myeloma market across the 7MM is poised for substantial growth in the coming years. This expansion is driven by a rising incidence of the disease, the increasing adoption of innovative therapies, and continuous efforts in research and development. While challenges such as relapse and drug resistance remain, the dynamic treatment landscape, marked by recent approvals and a promising pipeline, offers a positive outlook for the future of Multiple Myeloma management.

Table of Contents

Related Reports

Multiple Myeloma Pipeline Insight

Multiple Myeloma Pipeline Insight provides comprehensive insights about the Multiple Myeloma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Multiple Myeloma companies, including CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co. Ltd., GPCR Therapeutics, and Chimerix among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Myeloma Market Set for Robust Growth Across the 7MM | DelveInsight

“Rheumatoid Arthritis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.

The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years.

• Rheumatoid Arthritis companies working in the treatment market are Sonoma Biotherapeutics, OncoOne, Oryn Therapeutic, I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, and others, are developing therapies for the Rheumatoid Arthritis treatment

• Emerging Rheumatoid Arthritis therapies in the different phases of clinical trials are- SBT-77-7101, ON104, ORTD 1, TJ003234, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM0, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years

• In February 2025, AnaptysBio’s Phase IIb trial evaluating rosinilimab for rheumatoid arthritis (RA) has delivered promising results, with some patients achieving the highest recorded response rates by week 14. Remarkably, 69% of participants attained low disease activity. The U.S.-based company presented findings from its randomized RENOIR trial (NCT06041269), which assessed the safety and tolerability of rosinilimab in moderate-to-severe RA patients previously treated with conventional disease-modifying drugs. The study successfully met its primary endpoint, demonstrating a statistically significant improvement in DAS28-CRP scores compared to placebo, reinforcing rosinilimab’s potential as an effective RA treatment.

• In December 2024, XBiotech’s stock price dropped significantly after the company announced the termination of its clinical program in rheumatological diseases. This decision follows the evaluation of a Phase II trial for its arthritis treatment, Natrunix, which did not meet its primary endpoint. The Austin, Texas-based biotech firm saw a 27% decline in stock value after the trial (NCT05363917) revealed substantial irregularities, making it difficult to draw definitive conclusions from the study results.

• In October 2024, SetPoint Medical has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA), allowing it to start a clinical trial to test its modulation platform in relapsing-remitting multiple sclerosis (RRMS) patients. The multicenter, randomized, double-blind, sham-controlled pilot study will take place in the US and is set to begin in 2025. The US-based company plans to enroll 60 patients with the autoimmune disorder for the trial.

• In July 2024, Navidea Biopharma has decided to discontinue its rheumatoid arthritis (RA) program following unsatisfactory findings from an exploratory analysis of the NAV3-33 trial. The Phase III study (NCT05246280), which included 523 participants, aimed to validate the effectiveness of intravenous (IV) Lymphoseek (Tc 99m tilmanocept) imaging in predicting clinical outcomes in RA patients starting anti-tumor necrosis factor alpha (TNFα) therapy.

• In July 2024, Dutch biotech firm Citryll has completed subject dosing in the repeat-dose phase of its Phase I clinical trial for CIT-013, an anti-inflammatory drug candidate. This first-in-human study focuses on evaluating the safety and tolerability of the antibody. In the trial’s part D segment, the safety and tolerability of CIT-013 are further assessed through repeat dosing in a group of nine rheumatoid arthritis (RA) patients and three healthy volunteers.

Rheumatoid Arthritis Overview

Rheumatoid Arthritis (RA) is a chronic autoimmune disorder where the immune system mistakenly attacks the joints, causing inflammation. This leads to symptoms such as joint pain, swelling, stiffness, and reduced mobility, typically affecting both sides of the body (e.g., both hands or knees). Over time, RA can damage joint tissues, resulting in deformities and loss of function. It may also affect other organs, including the lungs, heart, and eyes. While the exact cause is unknown, genetics, environmental factors, and lifestyle may contribute. Treatment includes medications (like DMARDs and biologics), physical therapy, and lifestyle changes to manage symptoms and prevent progression.

Get a Free Sample PDF Report to know more about Rheumatoid Arthritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight

Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:

• SBT-77-7101: Sonoma Biotherapeutics

• ON104: OncoOne

• ORTD 1: Oryn Therapeutic

• TJ003234: I-Mab Biopharma Co. Ltd.

• TCK-276: Teijin Pharma

• IRL-201805: Revolo Biotherapeutics

• LY3462817: Eli Lilly and Company

• Dekavil: Philogen

• AP1189: SynAct Pharma

• RC18: RemeGen

• SM03: SinoMab Bioscience

• TS152: Taisho Pharmaceutical

• SM03: SinoMab

• SHR0302: Jiangsu Hengrui Medicine

• RC18: RemeGen

• Otilimab: GlaxoSmithKline

• ATI-450: Aclaris Therapeutics

• MBS2320: Modern Biosciences

• PF-06651600: Pfizer

• Obefazimod: Abivax

• ABBV-154: AbbVie

• Branebrutinib: Bristol Myers Squibb

• KPL-404: Kiniksa Pharmaceuticals

• ORTD-1: Oryn Therapeutics

• MRx0006: 4D pharma plc.

• LABP-69: Landos Biopharma, Inc

• BZ068: Biozeus

Rheumatoid Arthritis Route of Administration

Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Rheumatoid Arthritis Molecule Type

Rheumatoid Arthritis Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Rheumatoid Arthritis Pipeline Therapeutics Assessment

• Rheumatoid Arthritis Assessment by Product Type

• Rheumatoid Arthritis By Stage and Product Type

• Rheumatoid Arthritis Assessment by Route of Administration

• Rheumatoid Arthritis By Stage and Route of Administration

• Rheumatoid Arthritis Assessment by Molecule Type

• Rheumatoid Arthritis by Stage and Molecule Type

DelveInsight’s Rheumatoid Arthritis Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis pipeline report to learn more about the emerging Rheumatoid Arthritis therapies

Some of the key companies in the Rheumatoid Arthritis Therapeutics Market include:

Key companies developing therapies for Rheumatoid Arthritis are – Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., and others.

Rheumatoid Arthritis Pipeline Analysis:

The Rheumatoid Arthritis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.

• Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Rheumatoid Arthritis drugs and therapies

Rheumatoid Arthritis Pipeline Market Drivers

• Rising prevalence of arthritis and other joint disorders, rising combinational therapy of biologics for the treatment of Rheumatoid Arthritis, rich emerging pipeline, acceptance of biosimilars for treatment of Rheumatoid Arthritis are some of the important factors that are fueling the Rheumatoid Arthritis Market.

Rheumatoid Arthritis Pipeline Market Barriers

• However, high cost of biologics, low adherence to the drugs, lack of daily assessment of RA • Delay in RA diagnosis and other factors are creating obstacles in the Rheumatoid Arthritis Market growth.

Scope of Rheumatoid Arthritis Pipeline Drug Insight

• Coverage: Global

• Key Rheumatoid Arthritis Companies: Sonoma Biotherapeutics, OncoOne, Oryn Therapeutic, I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, and others

• Key Rheumatoid Arthritis Therapies: SBT-77-7101, ON104, ORTD 1, TJ003234, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM0, and others

• Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies

• Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers

Request for Sample PDF Report for Rheumatoid Arthritis Pipeline Assessment and clinical trials

Table of Contents

1. Rheumatoid Arthritis Report Introduction

2. Rheumatoid Arthritis Executive Summary

3. Rheumatoid Arthritis Overview

4. Rheumatoid Arthritis- Analytical Perspective In-depth Commercial Assessment

5. Rheumatoid Arthritis Pipeline Therapeutics

6. Rheumatoid Arthritis Late Stage Products (Phase II/III)

7. Rheumatoid Arthritis Mid Stage Products (Phase II)

8. Rheumatoid Arthritis Early Stage Products (Phase I)

9. Rheumatoid Arthritis Preclinical Stage Products

10. Rheumatoid Arthritis Therapeutics Assessment

11. Rheumatoid Arthritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Rheumatoid Arthritis Key Companies

14. Rheumatoid Arthritis Key Products

15. Rheumatoid Arthritis Unmet Needs

16 . Rheumatoid Arthritis Market Drivers and Barriers

17. Rheumatoid Arthritis Future Perspectives and Conclusion

18. Rheumatoid Arthritis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Eli Lilly and Company, Philogen, I-Mab Biopharma Co. Ltd., Teijin Pharma